TNFRSF8 and lymphoma: The most promising target so far is CD30, with Ramos et al. reporting a cohort of patients with CD30+ lymphoma, predominately Hodgkin’s lymphoma, that included a patient with ALK+ ALCL that achieved a CR that persisted for nine months [96,97].